Key Facts
Employees: more than 500
General Manager: Mr. Franck Savignard
Pharmaceutical activities
SKUs: more than 200
Markets: 35
Regulatory: European Local Authorities, FDA, ANVISA, ANSES
GDUFA: registered
Development: transfers, lyo cycle optimisation
API activities
Active Pharmaceutical Ingredients (CEP, DMF): 17
Regulatory: European Local Authorities, FDA, ANSES, PMDA
Development: yes
Sterile Dosage Forms Capacity (units per year)
Valdepharm has welcomed a major investment in 2015-2016 with 2 new lyophilisators of 35 sqm reaching now more than 160 sqm of capacity and a new pre-filled syringes (PFS) line.
Disposable bags handling allows to increase flexibility or to perform more efficiently clinical batches.
A specific know-how in handling viscous solution and suspension has also been developed.
Vials (lyo): more than 50 Mio units
Pre-filled syringes (PFS) : more than 25 Mio units
Ampoules: more than 15 Mio units
Sterile and non-sterile pharmaceutical ingredients
Reactor Capacity: 120 cubic meters
Glass-lined reactors: 20, from 400 to 10,000 L
Hastelloy reactors: 2, from 4,000 to 8,000 L
Filter dryers: 10 up to 6 sqm (incl. 316 L)
Centrifuges: 2 Hastelloy
Micronization: Yes, including aseptic
Milling: Impact and Airjet Mills
Location
API
- Estradiol
- Norethindrone
- Trazodone
- Trenbolone
- Chlormadinone
Equipment & Technologies
- Aseptic crystalization
- Steroid handling
- Hastelloy reactors
- Hastelloy centrifuges
- Aseptic micronization
- Impact and airjet mill
Reactions
- Epoxidation
- Baeyer Villiger
- Vilsmeier-Haack
- Halogenation
- Organometallics
- Phosphorylation
- Reduction
Pharmaceutical Sterile Dosage Forms
- Freezed dried vials
- Liquid vials
- Pre-Filled Syringes (PFS)
- Ampoules
- Disposable bags handling
- Controlled substances
Print site information